As EMA shifts to virtual meetings, agency doesn’t expect impact on drug assessments, safety monitoring

EMA says its assessment and monitoring of medicines hasn’t been affected by the COVID-19 pandemic, even as the agency transitions to virtual meetings.

The agency said Wednesday that all meetings of committees, working parties and stakeholder events hosted at its Amsterdam campus through the end of April will either be conducted virtually or postponed to later this year...